Return to HDA home page HDA Message Board
HDA About the HDA HDA What is HD HDA Juvenile HD HDA Children & Young People HDA Professionals HDA Resources HDA Research HDA HDA News HDA Events HDA Contact the HDA HDA Home Page

Outside of office hours if you need someone to speak to you can phone the Samaritans on 116 123

Go Back   HDA Message Board > Message Board Categories > Research, drugs, treatment, new diagnosis

Research, drugs, treatment, new diagnosis Forum for medical issues, and for the recently diagnosed (and families)

Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 21-02-18, 10:13 AM   #1
Approved Member
charliegirl's Avatar
Join Date: Jun 2013
Location: Lancashire
Posts: 118
Default Research

Hi . Wanted to share this - if people have already read it just ignore it😐but I found this interesting on a simplified level. Many of us who have the gene and have experience of family members with the gene have stories and experiences to highlight that hd is there - way before the current time that a Consultant will agree that the gene is affecting a persons life . I have always found this really frustrating as I feel like I am either exaggerating or making it up ! But it’s all fact I do understand tho that if it can’t be proved by science the Consultant can’t say that the issues are HD . As HD has changed way before the time line currently being accepted by many consultants because if the science isn’t there they won’t medically say it’s HD .
I am not having a go at Consultants - I respect mine so much and I respect the research and science so much - but families do often have different stories than science. Lv Charlie girl 🐶 keep plodding on HD family xx thanks again to all the fab Professionals involved in research and who work with families with HD xx

Rare disease research -
In the study, early abnormalities were found in the structure of neurons, as were large masses within cells that had never previously been reported. These findings are noteworthy considering that the disease doesn’t typically present until a patient reaches his or her middle age years. The data could lead to future clinical trials designed to evaluate new approaches and potentially effective therapies for HD patients.

“Our research supports the idea that the first domino is pushed soon after fertilization, and that has consequences down the line. The final domino falls decades after birth, when the symptoms are observable,” said Dr Brivanlou in a statement.

The CRISPR gene-editing technology was used in the engineering of human embryonic stem cell lines identical aside from the number of DNA repeats that occurred at the ends of their HTT genes.

"We started seeing things that were completely unexpected," says Brivanlou. "In cell lines with mutated HTT, we saw giant cells. It looked like a jungle of disorganization. Our work adds to the evidence that there is an unrecognized developmental aspect to the pathology. Huntington's may not be just a neurodegenerative disease, but also a neurodevelopmental disease."

Typically, when cells divide, they each retain one nuclei, however, some of the enlarged mutated cells displayed up to 12 nuclei, proposing that the generation of new neurons (neurogenesis) was effected. The more repeats there were, the more multinucleated neurons appeared, confirming that the disruption was directly proportional to how many repeats were present in the mutation.

While, historically, treatments for HD have mostly been aimed at blocking the activity of the mutant HTT protein, the recent data suggests that the brain disruption could possibly be due to a lack of HTT protein activity. Thus, the researchers created cell lines that completely lacked the HTT protein, which ended up presenting very similarly to those with HD pathology. It was concluded that the idea that a lack of the protein – not an excess of it – is driving the disease.

Before the study, scientists were unsure of the purpose of the HTT gene and could not predict cellular effects of the mutations. The findings are significant in that they led the researchers to believe that existing treatments, therapies that block HTT protein activity, may be doing more harm than good.

"We should rethink our approach to treating Huntington's,” Brivanlou said. "Both the role of the HTT protein and the timing of treatment need to be reconsidered; by the time a patient is displaying symptoms, it may be too late to medicate. We need to go back to the earliest events that trigger the chain reaction that ultimately results in disease so we can focus new therapies on the cause, not the consequences."

For more breakthroughs in the Huntington’s disease community, follow Rare Disease Report on Facebook and Twitter.
"Just keep swimming !"
charliegirl is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is Off
HTML code is Off

Forum Jump

All times are GMT +1. The time now is 04:05 PM.

About the HDA Message Board

A UK-based forum for people whose lives are affected by Huntington's disease and wish to share their experiences with others. Moderated by SHDAs from the HDA, a UK registered charity.

Please Remember

The HDA Message Board is not a substitute for professional advice. Consult a relevant professional before making decisions that could affect you or others.

Donate to HDA

Powered by vBulletin® Version 3.8.5
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
Registered Charity No. 296453. Website Content © HDA 2010